EODData

MEMBERSHIP REGISTER LOG IN

FRA, 2PQ: Organogenesis Holdings Inc

14 Aug 2026
LAST:

1.520

CHANGE:
 0.01		OPEN:
1.510		HIGH:
1.530		ASK:
0.000		VOLUME:
0
CHG(%):
0.65		PREV:
1.530		LOW:
1.500		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
14 Aug 261.5101.5301.5001.5200
13 Aug 261.5501.5701.5301.5300
12 Aug 261.6201.6201.5201.5500
07 Aug 261.6501.6501.3401.5800
06 Aug 262.0402.0402.0202.0400
05 Aug 262.0402.0402.0002.0200
04 Aug 262.0202.0602.0202.0200
03 Aug 262.0402.0802.0202.0200
31 Jul 262.1202.1202.0002.0200
30 Jul 262.1802.1802.0602.1000

PROFILE

Name:Organogenesis Holdings Inc
About:Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Sector:Healthcare
Address:85 Dan Road, Canton, MA, United States, 02021
Website:https://organogenesis.com
ISIN:US68621F1021
LEI:549300RLC2O821TU6941

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:16.62 
Forward P/E:4.52 
PEG Ratio:0.10 
Price to Sales:0.52 
Price to Book:1.25 
Profit Margin:0.01 
Operating Margin:-1.75 
Return on Assets:0.02 
Return on Equity:0.01 
Revenue:450.9M 
EBITDA:93.98M 
Shares:126.86M 
Market Cap:192.82M 

TECHNICAL INDICATORS

MA5:1.648.2%
MA10:1.8421.1%
MA20:2.0233.2%
MA50:2.0534.9%
MA100:2.0736.0%
MA200:2.8788.7%
RSI14:15.91 
WPR14:-100.00 
MTM14:-0.58
ROC14:-0.28 
ATR:0.12 
Week High:1.658.6%
Week Low:1.3413.4%
Month High:2.3252.6%
Month Low:1.3488.7%
Year High:5.75278.3%
Year Low:1.3413.4%
Volatility:17.30